Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

Inclusion Criteria

• •Patients with unresectable and chemotherapy resistant primary or recurrent carcinoma of colorectal, gastric or pancreatic origin
• •There must be pathologic evidence for malignancy with a soft tissue component of tumor evident on CT scan imaging or physical examination
• •Patient must be able to give informed consent
• •There must be an anticipated survival of at least 3 months
• •Performance status of 80-100 (Karnofsky performance status)
• •WBC count \>= 3,000uL
• •Platelet count \>= 100,000uL
• •Prothrombin time and partial thromboplastin time of \<= 1.5 times the upper limit of normal
• •Women of childbearing potential must have a negative pregnancy test; women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant during or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
• •Patients with asymptomatic small volume bone disease not likely to require radiation therapy during the period of the vaccine trial will be eligible
• •Hemoglobin level \> 9g/dL
• •There must be evidence of p53 over expression by immunohistochemistry with \> 10% of cells within the tumor strongly positive
• •Patients with colorectal cancer will need to have failed to respond to 5-FU based therapy with oxaliplatin, irinotecan as well as epidermal growth factor receptor (EGFR) directed therapies (if appropriate); patients with gastric cancer will need to have progressed on standard first line chemotherapy or chemoradiotherapy and Herceptin based therapy (if appropriate); patients with pancreatic cancer who have failed to respond to at least 1 chemotherapy regimen